Polymeric oncolytic adenovirus for cancer gene therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Joung-Woo | - |
dc.contributor.author | Lee, Young Sook | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.contributor.author | Kim, Sung Wan | - |
dc.date.accessioned | 2021-08-02T17:52:33Z | - |
dc.date.available | 2021-08-02T17:52:33Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-12 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/24785 | - |
dc.description.abstract | Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research. (C) 2015 Elsevier B.V. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | Polymeric oncolytic adenovirus for cancer gene therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.doi | 10.1016/j.jconrel.2015.10.009 | - |
dc.identifier.scopusid | 2-s2.0-84947228682 | - |
dc.identifier.wosid | 000365587800016 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.219, pp.181 - 191 | - |
dc.relation.isPartOf | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 219 | - |
dc.citation.startPage | 181 | - |
dc.citation.endPage | 191 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | METASTATIC PROSTATE-CANCER | - |
dc.subject.keywordPlus | DOUBLE-SUICIDE GENE | - |
dc.subject.keywordPlus | IMPROVED SYSTEMIC DELIVERY | - |
dc.subject.keywordPlus | HUMORAL IMMUNE-RESPONSES | - |
dc.subject.keywordPlus | I/II CLINICAL-TRIAL | - |
dc.subject.keywordPlus | PHASE-I TRIAL | - |
dc.subject.keywordPlus | BIOREDUCIBLE POLYMER | - |
dc.subject.keywordPlus | TUMOR-GROWTH | - |
dc.subject.keywordPlus | REPLICATION-COMPETENT | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordAuthor | Oncolytic adenovirus | - |
dc.subject.keywordAuthor | Clinical trials | - |
dc.subject.keywordAuthor | Cancer gene therapy | - |
dc.subject.keywordAuthor | Oncolytic Ad/polymer hybrid vector | - |
dc.subject.keywordAuthor | Active targeting | - |
dc.subject.keywordAuthor | Tumor microenvironment targeting | - |
dc.subject.keywordAuthor | Systemic administration | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.